We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+39.57%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.03B
AUM Growth
+$88.2M
Cap. Flow
-$124M
Cap. Flow %
-12.03%
Top 10 Hldgs %
68.92%
Holding
48
New
–
Increased
4
Reduced
21
Closed
8
Avg Time Held
19.2 quarters
Top 10 Avg Time Held
4 quarters
Top 20 Avg Time Held
5.5 quarters

Top Buys

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$9.02M
2
IDYA icon
IDEAYA Biosciences
IDYA
+$7.49M
3
IMNM icon
Immunome
IMNM
+$1.5M
4
NGNE icon
Neurogene
NGNE
+$449K

Top Sells

Rank Stock Value
1
KYMR icon
Kymera Therapeutics
KYMR
+$35.1M
2
REPL icon
Replimune Group
REPL
+$26.4M
3
HNGE icon
Hinge Health
HNGE
+$15.5M
4
BHVN icon
Biohaven
BHVN
+$10.3M
5
BSX icon
Boston Scientific
BSX
+$9.16M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
SRRK icon
1
Scholar Rock
SRRK
$4.78B
$145M 14.15%
3,904,456
-24,583
-0.6% -$860K
2018 Q2
29 quarters
KRYS icon
2
Krystal Biotech
KRYS
$9.56B
$117M 11.36%
661,388
-2,083
-0.3% -$312K
2018 Q4
27 quarters
STOK icon
3
Stoke Therapeutics
STOK
$1.47B
$98.1M 9.55%
4,175,542
-200,389
-5% -$3.43M
2019 Q2
25 quarters
ZYME icon
4
Zymeworks
ZYME
$1.77B
$63.3M 6.16%
3,705,750
-444,877
-11% -$6.37M
2020 Q1
22 quarters
ADCT icon
5
ADC Therapeutics
ADCT
$189M
$62.7M 6.1%
15,666,731
– –
2020 Q2
21 quarters
IMNM icon
6
Immunome
IMNM
$2.04B
$58.8M 5.72%
5,023,385
+151,160
+3% +$1.5M
2023 Q4
7 quarters
LIVN icon
7
LivaNova
LIVN
$4.17B
$48.5M 4.72%
926,799
-7,472
-0.8% -$376K
2021 Q1
18 quarters
RGNX icon
8
Regenxbio
RGNX
$457M
$45.3M 4.41%
4,693,389
-82,328
-2% -$728K
2017 Q1
34 quarters
AKRO icon
9
DELISTED
Akero Therapeutics
AKRO
$35.5M 3.45%
747,818
-26,493
-3% -$1.28M
2019 Q2
25 quarters
NRIX icon
10
Nurix Therapeutics
NRIX
$2.6B
$34M 3.31%
3,678,394
-54,494
-1% -$566K
2020 Q3
20 quarters
BEAM icon
11
Beam Therapeutics
BEAM
$2.42B
$33.7M 3.28%
1,387,559
-35,852
-3% -$713K
2020 Q1
22 quarters
COGT icon
12
Cogent Biosciences
COGT
$4.81B
$31.7M 3.09%
2,209,118
+761,078
+53% +$9.02M
2023 Q2
9 quarters
ABSI icon
13
Absci
ABSI
$1.52B
$25.1M 2.44%
8,253,316
– –
2021 Q3
16 quarters
NGNE icon
14
Neurogene
NGNE
$435M
$22.5M 2.19%
1,299,022
+22,346
+2% +$449K
2019 Q4
23 quarters
ETNB icon
15
DELISTED
89bio
ETNB
$21.7M 2.11%
1,473,136
-72,072
-5% -$735K
2023 Q1
10 quarters
IDYA icon
16
IDEAYA Biosciences
IDYA
$3.29B
$20.2M 1.96%
742,017
+309,523
+72% +$7.49M
2023 Q4
7 quarters
ANNX icon
17
Annexon
ANNX
$709M
$19.2M 1.87%
6,300,644
– –
2020 Q3
20 quarters
FATE icon
18
Fate Therapeutics
FATE
$229M
$16.2M 1.58%
12,872,946
– –
2015 Q2
41 quarters
RAPT icon
19
DELISTED
RAPT Therapeutics
RAPT
$14.3M 1.39%
552,594
-78,092
-12% -$1.02M
2022 Q1
14 quarters
STTK icon
20
Shattuck Labs
STTK
$529M
$13.2M 1.29%
5,539,724
– –
2020 Q4
19 quarters
SLDB icon
21
Solid Biosciences
SLDB
$589M
$11.7M 1.14%
1,899,342
-16,584
-0.9% -$97K
2024 Q4
3 quarters
SLN icon
22
Silence Therapeutics
SLN
$552M
$11.2M 1.09%
2,164,777
– –
2024 Q1
6 quarters
NUVB icon
23
Nuvation Bio
NUVB
$1.64B
$11.2M 1.09%
3,031,009
– –
2021 Q1
18 quarters
KROS icon
24
Keros Therapeutics
KROS
$219M
$8.74M 0.85%
552,506
– –
2024 Q1
6 quarters
CLDX icon
25
Celldex Therapeutics
CLDX
$2.19B
$8.46M 0.82%
327,008
-16,018
-5% -$371K
2020 Q2
21 quarters
1
2

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2025 Portfolio in Review

As of Q3 2025, Redmile Group held 48 positions worth $1.03B, up 9.4% from $940M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Redmile Group withdrew a net $124M in Q3 2025, closing 8 positions and reducing 21 holdings. Its most notable exit was Kymera Therapeutics, an estimated $35.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Redmile Group added an estimated $9.02M to Cogent Biosciences.

  • Redmile Group added most to Cogent Biosciences in Q3 2025, an estimated $9.02M increase.
  • Redmile Group's biggest Q3 2025 reduction was Replimune Group, cutting an estimated $26.4M.
  • Redmile Group fully exited Kymera Therapeutics in Q3 2025, selling an estimated $35.1M.
  • Redmile Group's ten largest holdings make up 69% of its $1.03B portfolio in Q3 2025.
  • Redmile Group opened 0 new positions and closed 8 in Q3 2025.
  • Redmile Group's portfolio value rose 9.4% quarter-over-quarter to $1.03B.

Based on Redmile Group's 13F filing for Q3 2025, filed 14 Nov 2025.